[A basic study of combination cancer immunotherapy with OK-432 and rIL-2--induction of lymphokine-activated killer (LAK) precursor cells in murine spleen by intravenous administration of OK-432].
Shimoda
K
K
Saito
T
T
Kobayashi
M
M
D000818:Animals; D001688:Biological Products / Q000494:pharmacology*; D005260:Female; D007376:Interleukin-2 / Q000494:pharmacology*; D007694:Killer Cells, Natural; D051379:Mice; D008809:Mice, Inbred C3H; D010844:Picibanil / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000494:pharmacology; D013154:Spleen / Q000187:drug effects / Q000276:immunology*
D001688:Biological Products; D007376:Interleukin-2; D011994:Recombinant Proteins; D010844:Picibanil